Avery 2014.
| Study characteristics | ||
| Methods |
Study design: secondary analysis of RCT Country: USA Data collection period: not stated Registry ID: not reported |
|
| Participants |
Number of participants: N = 230 Sample characteristics (at baseline): Age (mean): 55.6 years (SD 6.7); Sex (% male): 0% (0/230) Population category: general population; Specific population: postmenopausal women Nicotine dependence: not reported; Baseline cigarettes per day: 18.3 (SD 9.9); Motivation to quit: selected by motivation to quit |
|
| Interventions |
Behavioural support for smoking cessation: therapeutic sessions with motivational and cognitive behavioural techniques (NRT study); supervised relaxation programme (REST study) Pharmacological support for smoking cessation: assigned to use 21 mg nicotine or placebo patch for 3 months (NRT study); varenicline treatment for 12 weeks (REST study) Psychotherapeutic or psychoactive support for mental health or mood: received mood management – participants in the REST study undertook a supervised relaxation programme |
|
| Outcomes |
Definition of cessation used: self‐reported and biovalidated 7‐day point‐prevalence abstinence Cessation definition used for outcome(s) in this analysis: point‐prevalence abstinence Measure of biovalidation: exhaled CO level of ≤ 8 ppm; participants with discrepancies were coded as people who smoke Definition of people who continued smoking used: people who smoke – not reported abstinence in last 7 days; missed visits coded as people who smoke Time point(s) at which follow‐up was conducted: baseline, 6 and 12 weeks Outcome category: Depression Outcome measure(s): Center for Epidemiologic Studies Depression Scale (CESD; 10‐item) |
|
| Funding source | The Patrick and Catherine Weldon Donaghue Foundation, The University of Connecticut Center on Aging, and NIH grants R01 DA13334, R01DA024872, and M01 RR06192 (University of Connecticut General Clinical Research Center) and P50AA15632. GlaxoSmithKline Pharmaceuticals donated nicotine and placebo patches | |
| Author conflicts of interest | Authors declared no competing financial interests exist | |
| Notes | Outcome data source: Published data | |